Schulte S - Search Results

1

Prolonged in-vivo half-life of factor VIIa by fusion to albumin.

Weimer T, Wormsbächer W, Kronthaler U, Lang W, Liebing U, Schulte S. Weimer T, et al. Among authors: schulte s. Thromb Haemost. 2008 Apr;99(4):659-67. doi: 10.1160/TH07-08-0525. Thromb Haemost. 2008. PMID: 18392323

2

Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin.

Metzner HJ, Pipe SW, Weimer T, Schulte S. Metzner HJ, et al. Among authors: schulte s. Thromb Haemost. 2013 Nov;110(5):931-9. doi: 10.1160/TH13-03-0213. Epub 2013 Aug 29. Thromb Haemost. 2013. PMID: 24178510 Review.

3

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).

Zollner S, Schuermann D, Raquet E, Mueller-Cohrs J, Weimer T, Pragst I, Dickneite G, Schulte S. Zollner S, et al. Among authors: schulte s. J Thromb Haemost. 2014 Feb;12(2):220-8. doi: 10.1111/jth.12477. J Thromb Haemost. 2014. PMID: 24641308 Free PMC article.

4

Genetic fusion to albumin improves the pharmacokinetic properties of factor IX.

Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S. Metzner HJ, et al. Among authors: schulte s. Thromb Haemost. 2009 Oct;102(4):634-44. doi: 10.1160/TH09-04-0255. Thromb Haemost. 2009. PMID: 19806248

5

Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.

Zollner SB, Raquet E, Müller-Cohrs J, Metzner HJ, Weimer T, Pragst I, Dickneite G, Schulte S. Zollner SB, et al. Among authors: schulte s. Thromb Res. 2013 Aug;132(2):280-7. doi: 10.1016/j.thromres.2013.06.017. Epub 2013 Jul 5. Thromb Res. 2013. PMID: 23830969 Free article.

6

Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII.

Zollner S, Raquet E, Claar P, Müller-Cohrs J, Metzner HJ, Weimer T, Pragst I, Dickneite G, Schulte S. Zollner S, et al. Among authors: schulte s. Thromb Res. 2014 Jul;134(1):125-31. doi: 10.1016/j.thromres.2014.03.028. Epub 2014 Mar 19. Thromb Res. 2014. PMID: 24814969 Free article.

7

FVIII half-life extension by coadministration of a D'D3 albumin fusion protein in mice, rabbits, rats, and monkeys.

Pestel S, Beltz HW, Claar P, Lind H, Mischnik M, Raquet E, Andrews A, Simmonds J, Tomasetig V, Dower SK, Tjärnlund-Wolf A, Schulte S, Schmidt PM, Weimer T. Pestel S, et al. Among authors: schulte s. Blood Adv. 2020 May 12;4(9):1870-1880. doi: 10.1182/bloodadvances.2019000999. Blood Adv. 2020. PMID: 32374879 Free PMC article.

8

Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa.

Schulte S. Schulte S. Thromb Res. 2008;122 Suppl 4:S14-9. doi: 10.1016/S0049-3848(08)70029-X. Thromb Res. 2008. PMID: 18929521 Review.

9

Half-life extension through albumin fusion technologies.

Schulte S. Schulte S. Thromb Res. 2009 Dec;124 Suppl 2:S6-8. doi: 10.1016/S0049-3848(09)70157-4. Thromb Res. 2009. PMID: 20109653

10

Recombinant fusion protein linking factor VIIa with albumin (rVIIa-FP): Tissue distribution in rats.

Herzog E, Harris S, McEwen A, Henson C, Pragst I, Dickneite G, Schulte S, Zollner S. Herzog E, et al. Among authors: schulte s. Thromb Res. 2014 Aug;134(2):495-502. doi: 10.1016/j.thromres.2014.05.031. Epub 2014 May 29. Thromb Res. 2014. PMID: 24958222 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

309 results

Search Page

Filters